Quantitative Solid Phase Fluorescence Immunoassay of Rheumatoid Factor and C-Reactive Protein in Active Rheumatoid Arthritis

1987 ◽  
Vol 87 (2) ◽  
pp. 223-229 ◽  
Author(s):  
Grant W. Cannon ◽  
Marlene J. Egger ◽  
John R. Ward ◽  
Lona J. Blonquist ◽  
Linda B. Collette
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Active Rheumatoid Arthritis ◽  
Solid Phase ◽  
Fluorescence Immunoassay ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Patryk J. Drobinski ◽  
Anne C. Bay-Jensen ◽  
Morten A. Karsdal ◽  
Samra Sardar ◽  
Anne S. Siebuhr
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Early Time ◽  
Response To Treatment ◽  
C Reactive Protein ◽  
Tissue Remodelling ◽  
Reactive Protein ◽  
Effect Of Treatment ◽  
And Gender ◽  
Spearman’S Correlation

Abstract Objective Associations between rheumatoid arthritis (RA) and effect of treatment at the tissue levels are poorly understood. We investigated the scope of released extracellular matrix (ECM) metabolites as a consequence of tissue remodelling in patients treated with methotrexate (MTX) and tocilizumab (TCZ) compared to placebo. Methods Tissue metabolites from 387 RA patients treated with either TCZ (8 mg/kg) or MTX monotherapy (7.5–20 mg/kg) were measured at baseline and 8 weeks sera by validated ELISA assays. The levels of collagen biomarkers (C1M, C2M, C3M and C4M) together with C-reactive protein (CRP) and CRP metabolite (CRPM) were investigated. Baseline levels of biomarkers have been compared with 72 age- and gender-matched healthy controls. Comparison between treatment and response groups were done by ANCOVA, Spearman’s correlation and logistic regression adjusted for age, gender, BMI and disease duration. Results C1M and C3M were significantly (P < 0.05) inhibited by TCZ and C3M by MTX (P < 0.01) compared to placebo. C1M and C3M inhibition with TCZ was respectively 23% and 16% greater than that of MTX (P < 0.01 and P < 0.0001). C4M was inhibited by TCZ and MTX, but the effect of TCZ was 22% greater than MTX (P < 0.0001). TCZ and MTX had minimal effect on C2M levels. MTX had no effect on CRP and CRPM, whereas TCZ reduced their levels to 69% and 27% from baseline. Investigated biomarkers revealed a significant (P < 0.05) difference in biomarker profiles of MTX ACR50 treatment responders and non-responders. Change to week 8 in levels of C3M, C4M, CRP and CRPM in MTX patients correlated significantly (rho = 0.41 to 0.18, P < 0.0001 to 0.039) with change in disease activity (DAS28) at weeks 8, 16 and 24, whereas only CRP in TCZ patients (rho = 0.32 to 0.21, P < 0.0001 to 0.01). Conclusion Patients receiving TCZ treatment for 8 weeks had higher suppression of tissue remodelling and inflammatory biomarkers over patients treated with MTX. Measured biomarkers enabled for a discrimination of biomarker profiles of ACR50 treatment responding patients and identification of those who benefit at the early time point. Week 8 change in levels of C3M, C4M, CRP and CRPM significantly predicted clinical response to treatment and correlated with DAS28 at all time points. Trial registration ClinicalTrials.gov, NCT00109408. Date of registration: July 2005. Name of the registry: A Study to Assess the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis.

Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial

2010 ◽  
Vol 40 (3) ◽  
pp. 232-233 ◽  
Author(s):  
JE Pope ◽  
C Thorne ◽  
BP Haraoui ◽  
D Truong ◽  
E Psaradellis ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
C Reactive Protein ◽  
Reactive Protein

Evaluation of vascular endothelial growth factor levels in rheumatoid arthritis patients, with and without joint swelling; a comparison with erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor and anti-cyclic citruillnated protein

2017 ◽  
Vol 43 (1) ◽  
pp. 76-82
Author(s):  
Alper Gümüş ◽  
Cihan Coşkun ◽  
Hümeyra Öztürk Emre ◽  
Musa Temel ◽  
Berrin Berçik İnal ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Rheumatoid Factor ◽  
Sedimentation Rate ◽  
Vascular Endothelial ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Endothelial Growth Factor

AbstractIntroduction:The aim of our study was to investigate the vascular endothelial growth factor levels in joint swelling-positive and joint swelling-negative rheumatoid arthritis patients and to then examine the relationship between conventional parameters such as the erythrocyte sedimentation rate and the levels of C-reactive protein, rheumatoid factor, and anti-cyclic citrullinated protein.Methods:Fifty-nine (52 women and seven men) rheumatoid arthritis patients and 25 (20 women and five men) healthy individuals volunteered for this study. The patient group was divided into two sub-groups based on whether or not they exhibited joint swelling.Results:The levels of vascular endothelial growth factor in the joint swelling-negative group were significantly different from those in the joint swelling-positive group, but they were not different from those in the control group (p=0.001 and p=0.72, respectively). We investigated the correlation between vascular endothelial growth factor and C-reactive protein levels (r=0.37, p=0.001). We also evaluated the diagnostic adequacy of vascular endothelial growth factor and created a ROC curve. The area under the curve was calculated to be 0.767.Conclusion:Vascular endothelial growth factor is an adequate diagnostic biomarker and can successfully be used to predict the occurrence of rheumatoid synovitis based on local inflammation.

scholarly journals Discovering Rheumatoid Arthritis During Pregnancy

2021 ◽  
Vol 2 ◽  
pp. 18-19
Author(s):  
Fatoumata Diakité ◽  
Boureima Kodio ◽  
Seydou Diallo ◽  
Fanta Sangaré ◽  
MohomedineTouré Touré ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Visual Analogue Scale ◽  
Rheumatoid Factor ◽  
Analogue Scale ◽  
Morning Stiffness ◽  
Fetal Loss ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Inflammatory Syndrome ◽  
Peptide Antibodies

Rheumatoid arthritis is an autoimmune mechanism disease that preferentially affects women. Remission from rheumatoid arthritis has often been associated with pregnancy. A 29-year-old woman presented with symmetrical inflammatory polyarthralgias of the large and small joints with morning stiffness estimated at 5 hours, and the Visual Analogue Scale at 80/100 associated with the joint swelling onset 12th week of amenorrhea. She has no medical history, third pregnancy, and no fetal loss has been reported. The physical examination of the day objectified five painful joints and two swollen joints. Disease activity was moderate. There was a biological inflammatory syndrome with a C-Reactive Protein (CRP) at 37.9 mg. Rheumatoid factor was positive at 214 IU (Standard <14 IU), anti-citrullinated peptides antibodies at 99.6 IU (Standard <17 IU). The pregnancy revealed rheumatoid arthritis positive to rheumatoid factor and citrullinated cyclic anti-peptide antibodies.   

Sign in / Sign up

Export Citation Format

Share Document